The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | BSH 2018: updates in lymphoma research
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, of Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, gives an overview of the talks given regarding recent updates in lymphoma research at the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK. She discusses opportunities to improve outcomes for patients with lymphoma; assessing opportunities to analyze tumor biology through pathways and biomarkers to identify drugs and targets. Moreover, she discusses the difficulties we face with regards to the time frames of designing pharmaceutical trials, as well as logistical difficulties in introducing new drugs and agents into our treatment repertoire. Finally, she notes the importance of having data available from clinicians regarding the natural history of patients who are not receiving pharmaceutical treatment, in order for us to determine the exact benefit that they give us.
